Home » Why Biotech Stocks Have More Room To Rise – Premium Content

Biotech Smashed nasdaq

Why Biotech Stocks Have More Room To Rise – Premium Content

This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.

Otherwise, enjoy the column!

© 2019 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Join our 1,495 Daily Subscribers And Get This FREE Commentary In Your E-Mail! 

Follow Mike on StockTwits 

[widget id=”wordads_sidebar_widget-41″]

Why Biotech Stocks Have More Room To Rise

[widget id=”text-14″]

In this premium video, Michael discusses why he thinks the pullback on January 8 in Biotech stocks was likely not the start of a steeper decline. Plus he gives 2 stocks he likes in the space, plus review the charts of $FOLD, $NBIX, $IBB, and $XBI

 


[widget id=”adcontrol_sidebar_widget-3″]

On-Demand Content

Tesla Stock Escapes From Model 3 Disaster – Premium Content

Apple iPhone Shipment Maybe Better Than Feared

Why Biotech May Outperform In 2018 

Thinking About 2018


[widget id=”text-13″]

Photo Credit Via Flickr

Michael Kramer and the Clients of Mott Capital own shares of $ACAD $ALKS

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2017 Mott Capital Management, LLC. Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

#BIOTECH #STOCKS